Ms David Austin Allcott, APRN | |
9160 Hwy 83 N, Bldg M-35, Corrine, UT 84302-0707 | |
(435) 863-2881 | |
(435) 863-2882 |
Full Name | Ms David Austin Allcott |
---|---|
Gender | Male |
Speciality | Nurse Practitioner - Occupational Health |
Location | 9160 Hwy 83 N, Corrine, Utah |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1518080142 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
363LX0106X | Nurse Practitioner - Occupational Health | 361546-4405 (Utah) | Primary |
363LX0106X | Nurse Practitioner - Occupational Health | 361546-8900 (Utah) | Secondary |
Mailing Address | Practice Location Address |
---|---|
Ms David Austin Allcott, APRN Po Box 707, Atk Launch Systems Group, Brigham City, UT 84302-0707 Ph: (435) 863-2881 | Ms David Austin Allcott, APRN 9160 Hwy 83 N, Bldg M-35, Corrine, UT 84302-0707 Ph: (435) 863-2881 |
News Archive
Through a randomized, double-blind, placebo-controlled phase II clinical trial, researchers at University of California San Diego School of Medicine report that small doses of NGM282, a non-tumorigenic variant of an endocrine gastrointestinal hormone, can significantly and rapidly decrease liver fat content in patients with non-alcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH).
A Cancer Genomics Browser developed by researchers at the University of California, Santa Cruz, provides a new way to visualize and analyze data from studies aimed at improving cancer treatment by unraveling the complex genetic roots of the disease.
Politico Pro reports that if power shifts to the right the implementation of the health law could be minimized.
Ipsen today announced the preliminary results of a phase I trial in metastatic breast cancer with BN83495, Ipsen's lead and first-in-class orally available irreversible steroid sulfatase (STS) inhibitor.
› Verified 1 days ago